Regulatory T Cells in Leprosy Maintain Anti-Inflammatory Function
By LabMedica International staff writers Posted on 10 Aug 2022 |
Leprosy is caused by Mycobacterium leprae, an intracellular acid-fast bacillus and is complicated by episodes of inflammation called leprosy reactions. Leprosy reactions are important causes of nerve damage and illness.
Erythema Nodosum Leprosum (ENL), also called type 2 reaction, is a severe systemic immune-mediated complication of borderline and lepromatous leprosy. ENL causes high morbidity and thus requires immediate medical attention. The numbers of circulating regulatory T cells (Tregs) are increased in lepromatous leprosy (LL) but reduced in ENL, the inflammatory complication of LL.
Clinical Scientists at the London School of Hygiene and Tropical Medicine (London, UK) working with their colleagues at the Armauer Hansen Research Institute (Addis Ababa, Ethiopia) recruited 60 untreated patients with lepromatous leprosy (30 patients with ENL reactions and 30 patients without ENL reactions) in Ethiopia to better understand the loss of immune regulation in ENL. They took blood samples at two time points before and after prednisolone treatment and assessed if the regulatory T-cells in these patients are functionally competent to control inflammation.
Frozen peripheral blood mononuclear cells (PBMC) were thawed, washed and incubated with 20μL of CD25 micro beads II, processed and added to a MS column attached to a Magnetic Cell Sorter (MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany). Lymphocyte stimulation tests (LST) were performed. Supernatants were analyzed for cytokines using a Ready-Set-Go sandwich ELISA. Capture and biotinylated detection antibodies directed against IFN-γ, TNFα and IL-10 (Thermo Fisher Scientific, Altrincham, UK) were used employing 96-well flat-bottom polystyrene MaxiSorp ELISA plates. For all plates, the optical density (OD) at 450 nm was measured using a SpectraMax plus microplate reader (Molecular Devices, Wokingham, UK).
The investigators reported that the depletion of CD25+ cells from PBMCs was associated with enhanced TNFα and IFNγ responses to M. leprae stimulation before and after 24 weeks treatment of LL with multidrug therapy (MDT) and of ENL with prednisolone. The addition of autologous CD25+ cells to CD25+ depleted PBMCs abolished these responses. In both non-reactional LL and ENL groups mitogen (PHA)-induced TNFα and IFNγ responses were not affected by depletion of CD25+ cells either before or after treatment. Depleting CD25+ cells did not affect the IL-10 response to M. leprae before and after 24 weeks of MDT in participants with LL.
The depletion of CD25+ cells was associated with an enhanced IL-10 response on stimulation with M. leprae in untreated participants with ENL and reduced IL-10 responses in treated individuals with ENL. The enhanced IL-10 in untreated ENL and the reduced IL-10 response in prednisolone treated individuals with ENL were abolished by addition of autologous CD25+ cells.
The authors concluded that their findings confirmed that T cell unresponsiveness in LL is M. leprae antigen specific and can be reversed after treatment of LL with MDT or by depleting Tregs. The study has shown that Tregs cells do not affect the IL-10 response to M. leprae in individuals with LL. They have also shown that the suppressive function of Tregs in ENL is very likely intact. The pathogenesis of ENL is apparently associated with decreased number of Tregs, but not with loss of function. The study was published on July 22, 2022 in the journal PLOS Neglected Tropical Diseases.
Related Links:
London School of Hygiene and Tropical Medicine
Armauer Hansen Research Institute
Miltenyi Biotec
Thermo Fisher Scientific
Molecular Devices
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms